Drugdiscovery >> Drugs >> News
3008
Views
Orphan Drug designation for SGX94 for acute radiation syndrome - drugdiscovery.com
Orphan Drug designation for SGX94 for acute radiation syndrome - drugdiscovery.com


Soligenix’ innate defense regulator, SGX94, is a new class of short, synthetic peptides that accelerates resolution of tissue damage following exposure to a variety of agents including radiation, chemotherapy, bacterial pathogens and trauma.
Read More >>


Tags: orphan drug, SGX94, acute radiation syndrome, Soligenix, synthetic peptides - September 17, 2013
Related Articles
5475
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

7806
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

5931
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

6741
Views
ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A
After last week’s approval of Orphan Drug Designation to Alnylam Pharmaceuticals’ RNAi drug ALN-AT3 for the treatment of hemophilia B, this week it is for the treatment of hemophilia A . Read More >>

Tags: orphan, drug, ALN-AT3, Alnylam, RNAi, hemophilia

13685
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

6033
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

3275
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

1375
Views
Xarelto was rejected again Xarelto was rejected again
Xarelto is Bayer's and Johnson & Johnson's oral anticoagulant. FDA has voted agains it for the second time due to ACS. The drug said to be a treatment for acute coronary syndrome. Read More >>

Tags: acute coronary syndrome, acs, anticoagulant

8624
Views
Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV
FDA has approved an Orphan Drug Designation to Advaxis’ next generation immunotherapy drug ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer. Read More >>

Tags: Advaxis, ADXS-HPV, HPV, anal cancer, human papillomavirus, immunotherapy, drug

1062
Views
A drug against space radiation? A drug against space radiation?
A new drug was tested on mice which might be effective against space radiation and protects future astronauts. Synthetic triterpenoid produced nice results. Read More >>

Tags: astronauts, cancer, radiation, space, mice, animals Space Exploration

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013